Aims/hypothesis Transcription factor E3 (TFE3) has been shown to increase insulin sensitivity by activating insulinsignalling pathways. However, the role of TFE3 in glucose homeostasis is not fully understood. Here, we explored the possible therapeutic potential of TFE3 for the control of hyperglycaemia using a streptozotocin-induced mouse model of diabetes. Methods We achieved overabundance of TFE3 in streptozotocin mice by administering an adenovirus (Ad) or adenoassociated virus serotype 2 (AAV2). We also performed an oral glucose tolerance test (OGTT) and insulin tolerance test (ITT). To explore molecular mechanisms of blood glucose control by TFE3, transcriptional studies on the regulation of genes involved in hepatic glucose metabolism were performed using quantitative real-time PCR and chromatin immunoprecipitation assay. The binding site of TFE3 in the liver Gck gene promoter was identified using deletion and site-specific mutation studies. Results Overabundance of TFE3 resulted in reduced hyperglycaemia as shown by the OGTT and ITT in streptozotocin-treated mice. We observed that TFE3 can upregulate Gck in a state of insulin deficiency. However, glucose-6-phosphatase and cytosolic phosphoenolpyruvate carboxykinase mRNA levels were decreased by Admediated overexpression of Tcfe3. Biochemical studies revealed that the anti-hyperglycaemic effect of TFE3 is due to the upregulation of Gck. In primary cultured hepatocytes, TFE3 increased expression of Gck mRNA. Conversely, small interfering RNA-mediated knockdown of TFE3 resulted in a decrease in Gck mRNA. Conclusions/interpretation This study demonstrates that TFE3 counteracts hyperglycaemia in streptozotocin-treated mice. This effect could be due to the upregulation of Gck by binding of TFE3 to its cognitive promoter region.
Introduction
The liver is a critical organ for glucose homeostasis because glucose consumption and glucose production occur there during the feeding and fasting states, respectively. Within the liver, the enzyme liver-type glucokinase (GCK) phosphorylates glucose to generate glucose-6-phosphate [1] and is thought to be a rate-controlling enzyme for the sensing of blood glucose levels [2, 3] . Thus, an understanding of the molecular mechanisms that drive the regulation of the GCK gene and the enzymatic activity of GCK is critical for developing glucose-lowering drugs.
Gck expression is reduced in animal models of diabetes with insulin deficiency and insulin resistance [4, 5] . Insulin upregulates, whereas glucagon suppresses Gck expression in primary cultured hepatocytes, regardless of glucose concentration [6, 7] . Transcription factors involved in insulinmediated Gck upregulation include sterol regulatory element-binding protein 1c (SREBP-1c), hepatocyte nuclear factor-4 and hypoxia-inducible factor-1α [8, 9] .
Transcription factor E3 (TFE3) is a basic helix-loophelix protein that has been studied in the context of immunology and cancer. TFE3, which is encoded by Tcfe3 (also known as Tfe3) and produced in liver and adipose tissues, activates expression of the immunoglobulin gene [10] . Genes upregulated by TFE3 include Irs2, Akt1, Insig1 and Hk2, which are involved in insulin-signalling [11] . Specifically, Irs2 expression is upregulated by the concerted actions of TFE3 and forkhead box protein O1 [11] , and downregulated by SREBP-1c [12] . Via this mechanism, TFE3 may help protect against development of the metabolic syndrome and insulin resistance. Despite its role in insulin sensitivity, the precise role of TFE3 in the regulation of blood glucose levels is not fully understood.
In this study, we demonstrate that adenovirus (Ad)-mediated overexpression of Tcfe3 (Ad-Tcfe3) or adenoassociated virus serotype 2-mediated overexpression of Tcfe3 (AAV-Tcfe3) upregulates Gck expression in mouse liver and primary cultured hepatocytes. The introduction of Ad-Tcfe3 or AAV-Tcfe3 to a mouse model of streptozotocininduced diabetes led to increased expression of Gck in liver, resulting in reduced hyperglycaemia and improved glucose and insulin tolerance. These results indicate that TFE3 could improve glucose disposal by upregulating Gck expression under conditions of insulin deficiency. Therefore, TFE3 overabundance may be an alternative therapy for the reduction of hyperglycaemia and improvement of glucose sensitivity without insulin.
Methods
Animal experiments C57BL/6JJmsSlc (C57BL/6J) male mice (9 weeks old) obtained from Shizuoka Laboratory Centre (Hamamatsu, Japan) were fed a regular chow diet and housed under a 12 h light/12 h dark cycle. All animal experiments were approved by the Institutional Animal Care and Use Committee of Yonsei University Health System (Seoul, Republic of Korea).
Streptozotocin treatment and adenovirus administration
Streptozotocin was administered daily for two consecutive days to 9-week-old C57Bl/6J mice (25 g). Administration was done by intraperitoneal injection at a dose of 100 mg/kg body weight in freshly prepared sodium citrate buffer (pH 4.5). An injection of sodium citrate buffer alone was used as a buffer control. Glucose levels were measured every 2 days in blood drawn from the mouse tail vein using a glucose monitor (OneTouch SureStep; Life Scan, Milpitas, CA, USA). At 14 days after streptozotocin treatment, mice with a blood glucose level higher than 25 mmol/l on three consecutive days (n08) were used as streptozotocin mice and were divided into two subgroups, one receiving Ad-green fluorescent protein (GFP) (n04) and the other Ad-Tcfe3 injections (n04). For control, buffer-treated mice were also divided into two subgroups as in streptozotocin mice (n04 per subgroup). Ad-gfp or Ad-Tcfe3 (a generous gift from N. Yamada, Department of Internal Medicine, Metabolism and Endocrinology, University of Tsukuba, Tsukuba, Ibaraki, Japan) was injected at a level of 1×10 7 plaque-forming units (PFU) into the tail veins of buffer control or streptozotocin mice, respectively. After an OGTT, mice were housed for an additional 2 days to avoid any stress from OGTT. The incremental AUC of blood glucose was calculated after Ad injection. At 7 days after the Ad injection, during which mice had free access to food, mice were anaesthetised with Zoletil (30 mg/kg, via intramuscular injection) 4 h after an overnight dark cycle and laparotomy was performed. Blood samples were collected from the inferior mesenteric artery, and the whole liver was removed and frozen in liquid nitrogen for subsequent mRNA and protein preparation. The insulin levels in blood from the orbital sinus were measured 1 day before the Ad injection.
AAV2 production and administration Recombinant AAV2-Tcfe3 was produced as described in the electronic supplementary material (ESM) Methods.
Biodistribution of Ad-Tcfe3 and AAV2-Tcfe3 For details, see ESM Methods.
OGTT and insulin tolerance test At 5 days after the Ad injection, an OGTT was performed on mice that had fasted for 16 h. Glucose (20% wt/vol.) was administered orally using a feeding tube (2 g/kg body weight) and blood glucose levels were monitored at specific time points. For the insulin tolerance test (ITT), mice were fasted for 6 h and insulin (0.75 units/kg Humulin R; Eli Lilly, Indianapolis, IN, USA) was administered intraperitoneally. For the ITT, new sets of mice were used (n 03 for each subgroup, similarly to OGTT). The measurement of glucose levels and calculation of the AUC were as described above for the OGTT.
Serum metabolite measurements Serum insulin levels were measured by ELISA (Alpco Immunoassays, Salem, NH, USA). Other serum metabolites, such as cholesterol, triacylglycerol and NEFA were measured by an enzymatic method using an autoanalyser (Hitachi 7600: Hitachi Instruments, Tokyo, Japan) as per manufacturer's instructions.
Cell culture HepG2 cells, a human liver hepatocellular carcinoma cell line, were maintained according to a standard protocol. Primary hepatocytes isolated from C57BL/6J mice were prepared as described [13] . After incubation for 4 h, the medium was replaced with serum-free DMEM containing Ad. At 48 h after Ad infection, cells were lysed for RNA and protein preparation.
Small interfering RNAs Details of sequences and transfection of small interfering RNA (siRNA) are described in the ESM Methods.
Total RNA isolation and quantitative PCR Total RNA was isolated from mouse liver or primary cultured hepatocytes using an RNA extraction kit (Easy Spin; iNtRON, Gyeonggi-do, Korea), and cDNA was generated by a reverse transcription system (ImProm-II; Promega, Madison, WI, USA) according to the manufacturer's instructions. Changes in mRNA levels were calculated using the comparative C t method, with Rplp0 as the reference gene and buffer-controlled Ad-gfp as a calibrator. The sequences for gene-specific PCR primers are provided in ESM Table 1 .
Western blot analysis Total protein was extracted from mouse liver following a standard protocol. Anti-GCK (sc-7908 [H-88]; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-TFE3 (ab70008; Abcam, Cambridge, MA, USA) or anti-β-actin (A544; Sigma, St Louis, MO, USA) were used as respective specific antibodies. The bands were detected using an imager (LAS-3000 I; Fujifilm, Tokyo, Japan).
Generation of deletion constructs and site-specific mutations
Promoter luciferase reporter constructs were generated by amplifying the promoter region of human GCK (phGCK) (−1,000 to 158 bp) from HepG2 genomic DNA and inserted into the pGL4.14 vector (Promega). Serial deletion constructs of the GCK promoter were prepared by amplifying the indicated regions and subcloned into pGL4.14. Point mutations were introduced into putative TFE3 binding sites in the phGCK (−1,000 to 158 bp) by replacing the sequences with the indicated bases.
Transient transfection and luciferase assays HepG2 cells were plated in 12-well tissue culture dishes at a density of 2×10 5 cells per well in 1 ml medium. Expression plasmids for either wild-type or dominant-negative TFE3, the human GCK promoter construct containing the luciferase reporter gene (0.25 μg hGCK-Luc, −1,000 to 158 bp) and the Renilla luciferase plasmid were transfected using FuGENE 6 (Roche, Mannheim, Germany) at a ratio of 3:1. The total amount of transfected plasmid was adjusted to 0.5 μg by adding empty pcDNA.
Chromatin immunoprecipitation assay Chromatin immunoprecipitation (ChIP) experiments were performed as previously described [13] with HepG2 cells overproducing V5-tagged TFE3 or with mouse liver injected with Ad-Tcfe3. The primers used for the PCR of the promoter regions are shown in ESM Table 2 .
Statistical analysis
In vitro experiments (n03-5) were each performed in triplicate. For in vivo experiments, three to four animals were used in each subgroup. The data are presented as mean±SEM. All datasets were analysed for statistical significance using a two-tailed unpaired Student's t test. Values of p<0.05 were considered significant. Statistical analysis was carried out using SPSS (Ver. 11.5; SPSS, Chicago, IL, USA).
Results
Adenovirus-mediated overproduction of TFE3 reduced hyperglycaemia in streptozotocin mice To elucidate the effects of TFE3 on blood glucose control, Ad-Tcfe3 (1× 10 7 PFU) was administered to buffer control and streptozotocin mice whose body weight, and insulin and blood glucose levels were measured ( Fig. 1 ). There were no significant changes in body weight among the test groups, but the weight of streptozotocin mice decreased slightly (data not shown). Serum insulin levels were significantly decreased in streptozotocin mice compared with the nondiabetic control group (113 pmol/l vs <25 pmol/l, p<0.001). Streptozotocin mice showed increased blood glucose levels, reaching a maximum of 27.8 mmol/l by 14 days after the streptozotocin injection. In streptozotocin mice, blood glucose levels began to decrease 2 days after introduction of Ad-Tcfe3. This trend continued until day6 (Fig. 1b, c) . Introduction of Ad-Tcfe3 resulted in a slight decrease in blood glucose levels in buffer control mice. To study the long-term effect of TFE3 on blood glucose homeostasis, we constructed AAV-Tcfe3 and observed the long-term effect for 32 days (ESM Fig. 1a, b) . Although the blood glucoselowering effect of AAV-Tcfe3 was much less efficient than that of Ad-Tcfe3, blood glucose levels began to decrease in streptozotocin mice after 22 days (from 28.9 mmol/l to 25 mmol/l) (ESM Fig. 1 ). These data indicate that overabundance of TFE3 can increase the expression of glucosesensing genes in the liver, in turn contributing to a decrease in blood glucose levels.
TFE3 administration improves glucose tolerance in streptozotocin mice To examine the effects of TFE3 on postprandial glucose disposal, we performed an OGTT. At 15 min after administration of glucose, mice overproducing TFE3 showed improved glucose tolerance compared with GFP controls in the buffer control group (Fig. 2a, b) . Similarly, overabundance of TFE3 in streptozotocin mice resulted in significantly improved glucose tolerance (Fig. 2a, b) . The OGTT in AAV-Tcfe3-treated streptozotocin mice revealed significantly improved glucose tolerance at 60 min after glucose administration (p00.034) (ESM Fig. 1c, d ). An ITT showed that Ad-Tcfe3 significantly lowered blood glucose levels in streptozotocin mice when compared with Adgfp (Fig. 2c) . The per cent reduction in blood glucose concentration following the insulin injection was approximately 47.6% and 34.9% at 60 min, and 64.7% and 35.1% at 120 min in streptozotocin-treated Ad-gfp control and AdTcfe3 mice, respectively (Fig. 2c) . The absolute blood glucose values in the same groups were 7.5 mmol/l and 4.6 mmol/l at 60 min, and 11.7 mmol/l and 4.6 mmol/l at 120 min, respectively (Fig. 2d) . These data indicate that TFE3 may improve glucose tolerance and insulin responsiveness by upregulating genes involved in glucose-sensing.
Effects of Ad-Tcfe3 administration on lipid profiles and expression of lipogenic genes To observe the effects of TFE3 on lipid metabolism, we measured the concentrations of serum cholesterol, NEFA and triacylglycerol. As shown in Fig. 3a-c and ESM Fig. 2a-c , levels of these metabolites were not significantly affected by TFE3 levels. Additionally, we monitored mRNA levels of lipogenesis-related genes, including Srebf1, Fasn, Acaca, Elovl6 and Scd1. The expression of a majority of genes involved in lipid metabolism was increased in response to Ad-Tcfe3 in streptozotocin mice (p<0.05) (Fig. 3d-h ). Although lipogenic gene expression showed a modest increase in the liver, the serum lipid profile was not affected. Similarly, AAV mediated Tcfe3 overexpression did not affect lipogenic gene expression (ESM Fig. 2d-h ).
TFE3 upregulates Gck expression in streptozotocin mice
Quantitative real-time PCR revealed that Tcfe3 gene expression was maintained 6 days after the Ad-Tcfe3 injection (Fig. 4c) . Gene delivery of Tcfe3 to the liver may have been restricted because Tcfe3 mRNA levels were very low in skeletal muscle (ESM Fig. 3c ) and adipose tissue (data not shown). In the liver of control mice, Gck mRNA was increased in response to TFE3 overabundance. Although Gck mRNA expression was significantly reduced in streptozotocin mice, the introduction of Ad-Tcfe3 restored it to a level comparable to that of the control Ad-gfp group (Fig. 4a) . Slc2a2 (which encodes GLUT2) mRNA expression was not changed in the control group by Ad-Tcfe3 administration (Fig. 4b) . However, Slc2a2 expression in the Ad-gfp control group was increased in streptozotocin mice and decreased by TFE3 overabundance (Fig. 4b) . AAV-mediated Tcfe3 gene transfer resulted in the expression of Tcfe3 in liver, in turn resulting in increased Gck expression (ESM Fig. 3a, b) . Western blot revealed that GCK levels were well correlated with those of TFE3 (Fig. 4d,  ESM Fig. 3d ). In contrast, mRNA expression of G6pc and Pck1 were significantly decreased by Ad-Tcfe3 (p<0.05) (Fig. 4e, f) .
TFE3 activates Gck gene expression in primary hepatocytes
The administration of Ad-Tcfe3 to primary cultured hepatocytes resulted in an increase in Gck mRNA in a dosedependent manner in serum-free media (Fig. 5a ). However, Slc2a2 mRNA expression was not affected (Fig. 5b) . Levels of GCK were increased proportionately to the amount of AdTcfe3 (Fig. 5d) . One extra immunoreactive band of TFE3 was observed, which could be a variant form of TFE3 [11] . Administration of Tcfe3 siRNA to hepatocytes resulted in a corresponding decrease in Gck and Tcfe3 mRNA levels; however, Slc2a2 expression was not affected (Fig. 5e-g ). These data suggest that TFE3 may directly activate Gck expression in primary cultured hepatocytes.
Gck promoter activity is directly upregulated by TFE3 To evaluate the role of TFE3 in GCK expression, the promoter reporter construct, phGCK 1000, was co-transfected with the TFE3 expression vector into HepG2 cells. As shown in Fig. 6a , wild-type TFE3 activated phGCK 1000. However, this effect was suppressed, in a dose-dependent manner, by a dominant-negative form of TFE3, which lacks a transactivation domain [11] . A computer search (using Transcription Element Search Software; www.cbil.upenn.edu/cgi-bin/tess/ tess, 16 potential TFE3-binding sites within the −1,000 bp region of the GCK promoter: −808 to −803 bp, −613 to −608 bp and − 83 to −78 bp (Fig. 6b) . Deletion of the promoter from − 1,000 bp down to −800 bp or −50 bp resulted in a significant loss of TFE3-dependent luciferase activities, suggesting the presence of TFE3-response elements in the regions between − 1,000 to −800 bp and −200 to −50 bp (Fig. 6c) . Sitespecific mutations in the TFE3-binding sites of the GCK promoter revealed that the −808 to −803 bp and the −83 to − 78 bp sites are responsible for the TFE3-dependent activation of the GCK promoter (Fig. 6d) . Direct binding of TFE3 to these regions was confirmed by ChIP assay in HepG2 cells overproducing human TFE3 and in Ad-Tcfe3-transduced murine liver (Fig. 6e, f) .
Discussion
In the murine model, Ad-Tcfe3 was introduced to buffer control or streptozotocin-treated mice. In response to overabundance of TFE3, control mice showed a 1.5-fold increase in Gck mRNA (Fig. 4a) and protein (Fig. 4d) . This modest increase in Gck expression caused a slight decrease in blood glucose levels (Fig. 1b) and a significant improvement of glucose tolerance (Fig. 2a) . These results are supported by previous studies showing that a mild increase of hepatic Gck expression in control mice led to a corresponding decrease in blood glucose levels [14] without altering the basal metabolic profile. A mild increase in Gck expression also resulted in glucose tolerance dominated by hepatic mechanisms [15] . Previously, the injection of Ad-Tcfe3 did not induce Gck expression in control mice [11] . However, as shown by our OGTT and ITT (Fig. 2) , the administration of Ad-Tcfe3 significantly improved glucose disposal in control mice, an observation supported by the finding that small changes in hepatic Gck expression have a considerable impact on blood glucose levels in transgenic mice [2, 3, 16] . The TFE3-dependent increase in blood glucose disposal was more prominent in streptozotocin-treated mice than in control mice. In this model, severely depleted Gck mRNA expression was restored by overabundance of TFE3. In turn, symptoms of hyperglycaemia were relieved (Fig. 1c) due to improved glucose and insulin tolerance (Fig. 2) . In the streptozotocin mice, which have nearly fully depleted insulin levels (<25 pmol/l), the upregulation of Gck can be explained by the direct binding of TFE3 to the Gck promoter (Fig. 4, Fig. 6 ). Furthermore, administration of Ad-Tcfe3 to primary cultured hepatocytes maintained in serum-free media resulted in increased Gck mRNA levels (Fig. 5) . These data suggest that the anti-hyperglycaemic effect of TFE3 might be, in part, due to direct upregulation of Gck. However, because insulin levels in streptozotocin mice are not absolutely zero, it is possible that residual insulin in these mice still affects Gck expression. Indeed, it has been demonstrated that insulin-dependent activation of Akt in primary cultured hepatocytes was sufficient to induce Gck expression [17] . In addition, Akt, when overabundant due to TFE3 administration, needs insulin for its phosphorylation [11] , which is a key modification step in transmitting signals for downstream gene regulation. In streptozotocin-treated mice, the almost fully depleted levels of insulin could phosphorylate Akt through IRS-2. However, because insulin may not be the only Akt phosphorylation signalling pathway [18] , the precise mechanism of Akt overabundance and its accompanying phosphorylation when induced by TFE3 needs to be explored. It is speculated that the increased expression of Srebf1 induced by TFE3 in streptozotocin mice (Fig. 3d ) may increase Gck mRNA together with TFE3 levels. Overexpression of Gck resulted in resistance to streptozotocin [3] and to highfat diet-induced diabetes in mice [19, 20] . Furthermore, the restoration of Gck expression in Zucker diabetic fatty rats [21] and in mice deficient in liver-specific 3-phosphoinositidedependent kinase-1, which have defects in the metabolic actions of insulin [22] , normalised plasma glucose levels.
GCK plays a role in maintaining normal glucose levels in liver in the postprandial state. In this study, blood glucose levels of randomly fed, streptozotocin-treated mice were significantly decreased by Ad-Tcfe3 (Fig. 1b) . The OGTT and ITT (Fig. 2) showed that Ad-Tcfe3 decreased blood glucose levels in streptozotocin mice, an observation explained by the fact that Ad-Tcfe3 increased Gck expression. These results indicate that if hepatic levels of GCK are maintained, it is possible to dispose of glucose in the absence of insulin. Furthermore, Ad-Tcfe3-mediated overabundance of GCK did not cause hypoglycaemia (Fig. 1b) .
Expression of Slc2a2, a partner of GCK in the transport of glucose into hepatocytes, was significantly decreased by Ad-Tcfe3 injection into streptozotocin mice. Because Slc2a2 expression is increased in the state of hyperglycaemia [23] , it can be speculated that TFE3 downregulates Slc2a2 expression (Fig. 4b) , causing a decrease in hepatocyte glucose output. Additionally, the introduction of Ad-Tcfe3 and the subsequent increase in Gck expression may also have led to increased glucose trapping in hepatocytes, as inferred from the decreased blood glucose levels in streptozotocin mice.
Generally, streptozotocin mice show a disrupted hormone ratio, in which insulin levels are severely decreased and glucagon levels are higher, resulting in increased gluconeogenesis [24] . Even under high glucagon levels (data not shown), the lower blood glucose levels observed in fasting streptozotocin mice injected with Ad-Tcfe3 (Fig. 2a, d ) could have been due to decreased expression of G6pc and Pck1 (Fig. 4e, f) .
The ITT showed that insulin decreased blood glucose levels in mice injected with Ad-gfp or Ad-Tcfe3 (Fig. 2c) . In streptozotocin mice, increased blood glucose levels are caused by a depletion of insulin, rather than by insulin resistance. With regard to the ability of insulin to reduce blood glucose levels, mice injected with Ad-Tcfe3 exhibited a stronger response than those injected with Ad-gfp alone. In vivo, insulin stimulates the secretion of counterregulatory hormones, such as glucocorticoids, resulting in an increase in blood glucose levels. Therefore, because the injected insulin has a short half-life and is rapidly degraded, the inhibitory effects on gluconeogenesis in the liver may disappear. However, in streptozotocin mice injected with AdTcfe3, blood glucose levels were maintained at lower levels until 120 min because TFE3 suppresses the expression of G6pc and Pck1 (Fig. 4e, f) .
